Johannes Oldenburg

27.3k total citations · 7 hit papers
658 papers, 18.1k citations indexed

About

Johannes Oldenburg is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Johannes Oldenburg has authored 658 papers receiving a total of 18.1k indexed citations (citations by other indexed papers that have themselves been cited), including 470 papers in Hematology, 149 papers in Genetics and 136 papers in Molecular Biology. Recurrent topics in Johannes Oldenburg's work include Hemophilia Treatment and Research (385 papers), Platelet Disorders and Treatments (196 papers) and Blood Coagulation and Thrombosis Mechanisms (135 papers). Johannes Oldenburg is often cited by papers focused on Hemophilia Treatment and Research (385 papers), Platelet Disorders and Treatments (196 papers) and Blood Coagulation and Thrombosis Mechanisms (135 papers). Johannes Oldenburg collaborates with scholars based in Germany, United States and United Kingdom. Johannes Oldenburg's co-authors include R. Schwaab, Simone Rost, Clemens R. Müller, Matthias Watzka, Anna Pavlova, Osman El‐Maarri, Andreas Fregin, H.‐H. Brackmann, Johnny Mahlangu and A. Pavlova and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Johannes Oldenburg

620 papers receiving 17.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

2004 857 citations Vytautas Ivaškevičius, Johannes Oldenburg et al. profile →
Emicizumab Prophylaxis in Hemophilia A with Inhibitors

2017 759 citations Johannes Oldenburg, Johnny Mahlangu et al. profile →
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

2018 503 citations Johnny Mahlangu, Johannes Oldenburg et al. profile →
Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens

2015 281 citations Johannes Oldenburg Blood profile →
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors

2019 263 citations Johannes Oldenburg, Johnny Mahlangu et al. Blood profile →
Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH

2021 181 citations Johannes Oldenburg, Robert Klamroth et al. profile →
Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A

2023 100 citations Roshni Kulkarni, Johannes Oldenburg et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Johannes Oldenburg Germany	67	11.1k	4.1k	2.9k	1.6k	1.2k	658	18.1k
Joel M. Kremer United States	77	6.9k 0.6×	2.0k 0.5×	4.1k 1.4×	639 0.4×	991 0.8×	322	23.2k
Vicente Vicente Spain	53	4.5k 0.4×	2.1k 0.5×	1.2k 0.4×	248 0.2×	352 0.3×	497	11.4k
H.C. Hemker Netherlands	63	10.2k 0.9×	2.8k 0.7×	2.5k 0.9×	175 0.1×	984 0.8×	403	17.7k
Lawrie W. Powell Australia	63	8.6k 0.8×	1.4k 0.3×	6.3k 2.2×	482 0.3×	5.8k 4.7×	295	14.2k
Victor R. Gordeuk United States	57	6.5k 0.6×	1.8k 0.4×	6.6k 2.3×	171 0.1×	2.0k 1.6×	401	11.8k
Frederick W. Miller United States	76	1.9k 0.2×	4.6k 1.1×	1.9k 0.7×	546 0.3×	536 0.4×	436	19.7k
Carlo Brugnara United States	71	6.6k 0.6×	5.0k 1.2×	6.3k 2.2×	103 0.1×	1.5k 1.2×	270	16.6k
Bernard Klein France	72	6.6k 0.6×	7.4k 1.8×	1.5k 0.5×	290 0.2×	204 0.2×	390	17.4k
Seppo Parkkila Finland	65	2.1k 0.2×	9.4k 2.3×	2.2k 0.8×	247 0.2×	2.1k 1.7×	320	15.1k
Josef S Smolen Austria	69	3.8k 0.3×	4.8k 1.2×	1.8k 0.6×	454 0.3×	162 0.1×	342	20.7k

Countries citing papers authored by Johannes Oldenburg

Since Specialization

Citations

This map shows the geographic impact of Johannes Oldenburg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johannes Oldenburg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johannes Oldenburg more than expected).

Fields of papers citing papers by Johannes Oldenburg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Johannes Oldenburg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johannes Oldenburg. The network helps show where Johannes Oldenburg may publish in the future.

Co-authorship network of co-authors of Johannes Oldenburg

This figure shows the co-authorship network connecting the top 25 collaborators of Johannes Oldenburg. A scholar is included among the top collaborators of Johannes Oldenburg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johannes Oldenburg. Johannes Oldenburg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Müller, Jens, et al.. (2025). Endothelium Modulates the Prothrombotic Phenotype of Factor V Leiden: Evidence From an Ex Vivo Model. Arteriosclerosis Thrombosis and Vascular Biology. 45(3). 412–423.

Goldmann, Georg, Johannes Oldenburg, Frank A. Schildberg, et al.. (2025). Physical activity and handgrip strength in patients with mild, moderate and severe haemophilia: Impacts on bone quality and lean mass. PLoS ONE. 20(3). e0319951–e0319951.

Pezeshkpoor, Behnaz, et al.. (2024). Comprehensive evaluation of anti-emicizumab antibodies in acquired hemophilia A: a detailed case study and methodological evaluation. Journal of Thrombosis and Haemostasis. 23(1). 85–96. 2 indexed citations

Hagelueken, Gregor, Deniz Ugurlar, Amit Sharma, et al.. (2024). Cryo-EM structure of the human native plasma coagulation factor XIII complex. Blood. 145(4). 438–449. 4 indexed citations

Oldenburg, Johannes, C. R. M. Hay, Flora Peyvandi, et al.. (2024). Superior Prophylactic Effectiveness of a Recombinant FVIIIFc Over Standard Half‐Life FVIII in Hemophilia A: A‐SURE Study. European Journal Of Haematology. 114(2). 248–257.

Oldenburg, Johannes, Susan Halimeh, Georgina Hall, et al.. (2023). Design of a Real-World Observational Study in Previously Untreated and Minimally Treated Hemophilia A Patients: Protect-NOW. SHILAP Revista de lepidopterología. 7(2). e110–e116. 1 indexed citations

Rezende, Suely Meireles, Jan Voorberg, Maria Elisa Mancuso, et al.. (2023). Determinants of successful immune tolerance induction in hemophilia A: systematic review and meta-analysis. Research and Practice in Thrombosis and Haemostasis. 7(1). 100020–100020. 6 indexed citations

Lowe, Gillian, Lone Hvitfeldt Poulsen, Susan Shapiro, et al.. (2023). Real-World Effectiveness of rFIXFc Prophylaxis in Patients with Haemophilia B Switched from Standard Half-Life Therapy in Three European Countries. Advances in Therapy. 40(9). 3770–3783. 4 indexed citations

Román, María, Giancarlo Castaman, Tadashi Matsushita, et al.. (2021). Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A. BMJ Open. 11(9). e044997–e044997. 3 indexed citations

10.

Akhter, Mohammad Suhail, et al.. (2021). SARS-CoV-2 Infection: Modulator of Pulmonary Embolism Paradigm. Journal of Clinical Medicine. 10(5). 1064–1064. 6 indexed citations

11.

Oldenburg, Johannes, Roshni Kulkarni, Alok Srivastava, et al.. (2017). Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein. Haemophilia. 24(1). 77–84. 38 indexed citations

12.

Sharma, Amit, Oliver Kaut, Anna Pavlova, et al.. (2017). Skewed X-chromosome inactivation and XIST locus methylation levels do not contribute to the lower prevalence of Parkinson's disease in females. Neurobiology of Aging. 57. 248.e1–248.e5. 11 indexed citations

13.

Rühl, Heiko, et al.. (2016). In Vitro Evaluation of Aptamer-Based Reversible Inhibition of Anticoagulant Activated Protein C as a Novel Supportive Hemostatic Approach. Nucleic Acid Therapeutics. 26(6). 355–362. 16 indexed citations

14.

Biswas, Arijit, et al.. (2016). Intron retention resulting from a silent mutation in the VWF gene that structurally influences the 5′ splice site. Blood. 128(17). 2144–2152. 30 indexed citations

15.

Santagostino, Elena, U. Martinowitz, Toshko Lissitchkov, et al.. (2016). Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood. 127(14). 1761–1769. 150 indexed citations

16.

Goering, Wolfgang, Albertas Daukša, Arijit Biswas, et al.. (2015). Inter-locus as well as intra-locus heterogeneity in LINE-1 promoter methylation in common human cancers suggests selective demethylation pressure at specific CpGs. Clinical Epigenetics. 7(1). 17–17. 30 indexed citations

17.

Glorioso, Thomas J., John M. Kittelson, M L Manco-Johnson, et al.. (2013). Natural History Of Hemophilic Joint Disease Using Sensitive Imaging With Magnetic Resonance Imaging (MRI). Blood. 122(21). 209–209. 2 indexed citations

18.

Geiser, Franziska, Rupert Conrad, Katrin Imbierowicz, et al.. (2011). Coagulation activation and fibrinolysis impairment are reduced in patients with anxiety and depression when medicated with serotonergic antidepressants. Psychiatry and Clinical Neurosciences. 65(5). 518–525. 38 indexed citations

19.

Kaiser, Rolf, et al.. (1994). Parallel Evolution in the V3 Region of HIV Type 1 after Infection of Hemophiliacs from a Homogeneous Source. AIDS Research and Human Retroviruses. 10(12). 1669–1678. 11 indexed citations

20.

Kaiser, Rolf, J P Kleim, Johannes Oldenburg, et al.. (1993). Diversification of HIV-1 Strains after Infection from a Unique Source. AIDS Research and Human Retroviruses. 9(2). 153–157. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact